# Erythema Multiforme

Manage suspected erythema multiforme by first excluding Stevens-Johnson syndrome/toxic epidermal necrolysis, then identifying herpes simplex virus, respiratory infection, or medication exposure to guide testing, lesion-directed care, referral, and prevention of recurrent disease.

**Clinical question:** How should physicians distinguish erythema multiforme from SJS/TEN and direct trigger-specific evaluation and management?

Updated: 2026-09-15T23:19:33.009189+00:00

## What matters in practice
- Symmetric, acral crops of classic three-zone target lesions with no systemic symptoms and no more than one mucosal surface favor erythema multiforme; widespread irregular macules, skin detachment, or involvement of at least two mucosal surfaces requires evaluation for SJS/TEN. [18]
- Ask specifically about recurrent herpes, respiratory illness, and recent medication exposure: HSV, Mycoplasma pneumoniae, and drug reactions are repeatedly implicated triggers. [16][17][23]
- A patient with blistering, desquamation, mucosal involvement, fever, or ocular disease should not be managed as uncomplicated cutaneous erythema multiforme. [1][2][3][11][18]
- For recurrent HSV-associated erythema multiforme, continuous acyclovir prophylaxis has trial support; a reported case used prophylactic acyclovir for 6 months. [13][15]
- Direct immunofluorescence is generally nonspecific in erythema multiforme; use biopsy-based immunopathology selectively when an autoimmune blistering disorder is a consequential alternative diagnosis. [4][7]

## Separate uncomplicated erythema multiforme from SJS/TEN at presentation

The immediate disposition hinges on mucosal burden, systemic illness, and epidermal injury.

Classify as probable uncomplicated erythema multiforme when lesions occur in symmetric crops on the extremities—particularly dorsal hands and forearms, palms, or soles—with a dark center, pale inner ring, and red outer ring. Erythema multiforme may involve one mucosal surface, but the expected course is self-limited and without systemic symptoms. [18]

Escalate immediately when the eruption is accompanied by fever, blistering, desquamation, denuded skin, or extensive mucosal disease. SJS/TEN may begin with widespread irregular red macules or patches, develop central vesicles or bullae, and involve skin plus mucous membranes; involvement of at least two mucosal surfaces is a defining high-risk pattern in the cited clinical guidance. [18]

Obtain urgent ophthalmology assessment for any ocular involvement, because prompt eye evaluation is recommended to prevent severe ocular complications. [11] Treat a patient with suspected SJS/TEN, substantial epidermal detachment, or multisite mucosal disease as a severe cutaneous adverse reaction rather than applying an outpatient erythema multiforme pathway. [18][24]
- Document the number of involved mucosal surfaces and whether oral intake is limited; more than one affected surface shifts concern toward SJS/TEN. [18]
- Inspect for bullae that have ruptured into denuded areas and for widespread irregular macules rather than primarily acral classic targets. [18]
- Ask about fever at onset or during progression; fever with severe rash is an escalation trigger. [1][2][3]

*Clinical pattern that changes immediate disposition. [18]*

| Feature | Pattern favoring erythema multiforme | Pattern requiring SJS/TEN evaluation |
| --- | --- | --- |
| Lesion distribution and morphology | Symmetric crops of three-zone target lesions on extremities, especially hands, forearms, palms, or soles. [18] | Widespread irregular erythematous macules or patches, potentially with central vesicles or bullae. [18] |
| Mucosal involvement | Absent or limited to no more than one mucosal surface. [18] | At least two mucosal surfaces involved. [18] |
| Systemic findings | No systemic symptoms. [18] | Fever, ruptured blisters, or denuded skin. [1][2][3][18] |
| Next action | Evaluate likely trigger and manage symptoms if disease is skin-limited and stable. [18][21] | Urgent severe-cutaneous-reaction assessment; obtain ophthalmology evaluation if eyes are involved. [11][18] |

## Use exposure pattern to target the workup

A trigger history determines whether to pursue HSV, respiratory, or medication-related causes.

Ask whether target lesions followed a recent or recurrent herpes episode. HSV is the most commonly reported cause of erythema multiforme, with estimates ranging from 15% to 63% across populations; recurrent herpes was the principal reported risk factor for erythema multiforme majus in one clinical-pattern study. A reproducible herpes-to-eruption sequence supports HSV-associated erythema multiforme and makes recurrence prevention clinically relevant. [8][16][17][19]

For patients with a preceding upper-respiratory syndrome, cough, or pneumonia-compatible illness—particularly children without clear herpes or drug exposure—consider Mycoplasma pneumoniae testing with serology and nasal PCR, plus a respiratory viral panel. In a retrospective emergency-department series, pediatric cases were most often attributed to upper respiratory infection, followed by M pneumoniae and medications. [16]

Construct a complete medication timeline before labeling an eruption idiopathic. Drugs are a recognized cause of erythema multiforme and are central in the differential from severe drug reactions. If there is a plausible culprit exposure plus blistering, desquamation, fever, or extensive mucosal involvement, stop treating the presentation as straightforward erythema multiforme and evaluate for a severe cutaneous adverse reaction. [17][23][24]
- Recurrent episodes with a herpes prodrome or recent herpes recurrence: classify as probable HSV-associated erythema multiforme and discuss suppressive antiviral therapy if episodes are clinically consequential. [13][15]
- Respiratory illness without a clear HSV or drug trigger: obtain Mycoplasma serology, nasal PCR, and a respiratory viral panel in pediatric patients. [16]
- Recent medication exposure with systemic or destructive cutaneous features: prioritize culprit-drug assessment and SJS/TEN exclusion. [9][24]

### When biopsy and immunofluorescence change management

Do not use direct immunofluorescence as a routine confirmation test for typical erythema multiforme, because results are generally nonspecific and may show labeling of apoptotic bodies or granular C3 deposition. [7] Obtain lesional biopsy with direct immunofluorescence and immunoblotting when a polymorphous bullous eruption raises concern for an autoimmune blistering disorder; epidermal and junctional deposits on direct immunofluorescence and anti-plakin antibodies on immunoblotting support paraneoplastic pemphigus in the cited diagnostic example. [4]

*Trigger-directed testing and the resulting next step. [16][17][23]*

| Clinical branch | Targeted evaluation | Result or pattern that changes management |
| --- | --- | --- |
| Recurrent herpes temporally linked to eruptions | Focused history for recent or recurrent herpes episodes. [8][16][19] | A recurrent temporal association supports HSV-associated erythema multiforme and consideration of continuous acyclovir prophylaxis. [13][15] |
| Respiratory prodrome, especially in children | Mycoplasma serology, nasal PCR, and respiratory viral panel when no clear herpes or drug exposure is present. [16] | An identified respiratory trigger directs management toward the associated illness and avoids an unsupported idiopathic label. [16] |
| Plausible medication exposure | Medication chronology and assessment for severe cutaneous adverse reaction features. [17][24] | Blistering, desquamation, fever, or substantial mucosal disease mandates SJS/TEN-focused escalation. [1][2][3][18] |
| Atypical bullous or polymorphous disease | Biopsy with direct immunofluorescence; add immunoblotting for anti-plakin antibodies when paraneoplastic pemphigus is suspected. [4][7] | Epidermal and junctional deposits plus anti-plakin antibodies support paraneoplastic pemphigus rather than ordinary erythema multiforme. [4] |

## Manage skin-limited disease symptomatically and escalate mucosal or severe disease

Treatment intensity should match disease extent and the likelihood of a severe mimic.

For skin-limited erythema multiforme without systemic symptoms or mucosal involvement, symptomatic management is generally sufficient because the condition is self-limited. Mild cases can be treated with topical corticosteroids. [11][18][21]

Do not allow symptomatic treatment to delay escalation in a patient with ocular disease, inability to maintain oral intake from mucosal involvement, fever, blistering, or desquamation. The referral threshold in the cited standard treatment guidance is all patients except those with rash limited to skin and no systemic symptoms or mucosal involvement. [18] Obtain ophthalmology evaluation for any eye involvement. [11]

Systemic corticosteroids have been reported to control erythema multiforme outbreaks, but maintenance use is not clearly indicated. [12] Reserve a systemic-corticosteroid decision for selected severe episodes after reassessing for SJS/TEN and trigger-related mimics; do not use maintenance corticosteroids as a recurrence-prevention substitute when HSV-associated recurrent disease is the working diagnosis. [12][13][15]
- Skin-limited, stable disease: use topical corticosteroids for mild cases and provide symptomatic care. [11][21]
- Ocular involvement: arrange ophthalmology assessment. [11]
- More than one mucosal surface, systemic symptoms, blistering, or denudation: refer/escalate rather than manage as uncomplicated erythema multiforme. [18]
- Consider systemic corticosteroids only for outbreak control; maintenance benefit is unclear. [12]

*Management by severity and recurrence pattern. [11][12][13][18][21]*

| Presentation | Immediate action | Avoid or reconsider |
| --- | --- | --- |
| Skin-limited, no systemic symptoms | Symptomatic treatment; topical corticosteroids are an option for mild disease. [11][21] | Routine referral is not required under the cited referral criterion. [18] |
| Mucosal involvement or systemic symptoms | Refer or escalate; reassess morphology and mucosal extent for SJS/TEN. [18] | Do not treat as low-risk skin-limited erythema multiforme. [18] |
| Ocular involvement | Obtain ophthalmology assessment. [11] | Do not defer eye evaluation because severe ocular complications may occur. [11] |
| Recurrent HSV-associated disease | Consider continuous acyclovir prophylaxis; a reported regimen duration was 6 months. [13][15] | Do not use long-term systemic corticosteroids as maintenance therapy; maintenance benefit is unclear. [12] |

## Prevent recurrent HSV-associated erythema multiforme with antiviral suppression

Recurrence linked to herpes requires a prevention plan rather than repeated treatment of isolated eruptions.

When recurrent erythema multiforme consistently follows herpes episodes, continuous acyclovir therapy is supported by a double-blind, placebo-controlled trial cited in the HSV treatment literature. [15] A published recurrent herpes-associated case used prophylactic acyclovir for 6 months. [13] Use the temporal association with herpes—not merely a remote HSV history—to identify the patients most likely to benefit from suppressive treatment. [8][13][19]

The provided evidence does not specify a prophylactic acyclovir dose, renal adjustment, or laboratory-monitoring schedule. Select the regimen using current antiviral prescribing guidance and patient-specific renal function, while reassessing whether recurrences continue to track with herpes activity. [13][15]

If new episodes occur despite a presumed HSV association, repeat the medication and respiratory-exposure review and reconsider alternate diagnoses when morphology becomes bullous, widespread, or atypical. Direct immunofluorescence is nonspecific for ordinary erythema multiforme but can support investigation of a competing autoimmune blistering diagnosis in the appropriate clinical context. [4][7][17][23]
- Document herpes timing for each recurrence; a consistent relationship is the key selection feature for HSV-directed prophylaxis. [8][13][19]
- Use a planned suppressive-treatment interval with reassessment; 6 months is reported in a recurrent HSV-associated case. [13]
- Reclassify rather than simply repeat treatment if lesions develop widespread irregular macules, bullae, denudation, fever, or multisite mucosal disease. [18]

*Recurrence strategy for suspected HSV-associated erythema multiforme. [8][13][15][19]*

| Clinical finding | Interpretation | Next action |
| --- | --- | --- |
| Recurrent eruptions after recent or recurrent herpes | Supports HSV-associated erythema multiforme. [8][19] | Consider continuous acyclovir suppression; a 6-month prophylactic course is reported. [13][15] |
| No reproducible herpes relationship | HSV attribution is less secure; other infectious and medication triggers remain relevant. [16][17][23] | Reassess respiratory illness, Mycoplasma testing when indicated, and drug exposure. [16][17] |
| Changed morphology or severe systemic/mucosal features | Possible SJS/TEN or alternate bullous disorder rather than recurrent uncomplicated erythema multiforme. [4][18] | Escalate assessment; use biopsy-based immunopathology selectively for a consequential blistering-disease differential. [4][7] |

## References
1. [PDF] These highlights do not include all the information ... - DailyMed — www.dailymed.nlm.nih.gov — https://www.dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=3b244bb3-2e8b-4fde-b69d-330aca56fb8e&type=pdf
2. [PDF] ATRIPLA ACCESS - DailyMed — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=7af4b5e9-f5bb-410c-8370-f74e04e7683b
3. [PDF] These highlights do not include all the information needed to use ... — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=2096a07e-8601-4bdc-ba5a-338a40cd02e9&type=pdf
4. A polymorphous bullous dermatosis - The Lancet Oncology — www.thelancet.com — https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30461-8/fulltext
5. Multiforme and Stevens-Johnson Syndrome - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/articlepdf/559054/archderm_133_7_008.pdf?resultClick=1
6. Necrolytic Acral Erythema Associated With Hepatitis C - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/190290
7. Erythema multiforme - eClinicalMedicine - The Lancet — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00488-7/fulltext
8. Correlations Between Clinical Patterns and Causes of Erythema ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/478935
9. Assessment of Need for Improved Identification of a Culprit Drug in ... — jamanetwork.com — https://jamanetwork.com/journals/jamadermatology/fullarticle/2806330
10. Herpes Simplex Virus Pneumonia: Clinical, Virologic ... - ACP Journals — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-97-6-813
11. Erythema multiforme, Stevens‐Johnson syndrome/toxic epidermal ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/ddg.14118
12. Erythema multiforme: diagnosis, clinical manifestations and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0714.2010.00912.x
13. Erythema Multiforme Attributable to Herpes Simplex Virus: Clinical ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2021/6692495
14. A systematic review on mucocutaneous presentations after COVID ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/dth.15461
15. Clinical Manifestations and Treatment Considerations of Herpes ... — academic.oup.com — https://academic.oup.com/jid/article-pdf/186/Supplement_1/S71/18008626/186-Supplement_1-S71.pdf
16. Herpes associated erythema multiforme: A retrospective study - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0735675720304435
17. Triggers, clinical manifestations, and management of pediatric erythema multiforme: A systematic review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0190962219303512
18. [PDF] STANDARD TREATMENT GUIDELINES AND ESSENTIAL ... — extranet.who.int — https://extranet.who.int/ncdccs/Data/ZAF_NCD_D1_Primary-Health-Care-level-2014_v3.0.pdf
19. Herpes Simplex | Pediatrics In Review - AAP Publications — pedsinreview.aappublications.org — https://pedsinreview.aappublications.org/content/30/4/119.full.print
20. Mycoplasma pneumoniae and Atypical Stevens-Johnson Syndrome — pediatrics.aappublications.org — https://pediatrics.aappublications.org/content/119/4/e1002
21. “Urticaria Multiforme”: A Case Series and Review of Acute Annular ... — pediatrics.aappublications.org — https://pediatrics.aappublications.org/content/119/5/e1177
22. [PDF] Good clinical diagnostic practice — applications.emro.who.int — https://applications.emro.who.int/dsaf/dsa236.pdf
23. New bullous lesions in a 72-year-old woman — www.ccjm.org — https://www.ccjm.org/content/88/6/319
24. Practical Guidance for the Evaluation and Management of Drug ... — www.jaci-inpractice.org — https://www.jaci-inpractice.org/article/S2213-2198(20)30812-6/pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.